Monday, 16 November 2026
Rīga TV

World and Latvian news in one place

AgriculturePublished: 16 November 2026 at 17:01

UK startup Zya raises $15m for an enzyme that turns sugar into fiber after eating

UK-based Zya has raised a £11.5m ($15m) Series A to develop Convero, an enzyme that converts around 30% of sucrose into prebiotic fiber after consumption, so food makers need not reformulate their products.

Foto: AgFunderNews (agrotehn.)

Zya, a UK-based biotech startup, has closed a Series A funding round of £11.5m (about $15m), led by the investment firm Astanor. The money will go towards human studies, regulatory work and commercial partnerships, as Zya aims to launch its first products with US food manufacturers by the end of 2027. The technology matters because it could change the nutritional impact of sugar without altering a food's recipe.

The company's first ingredient, Convero, is an enzyme made through precision fermentation. Zya says it converts roughly 30% of sucrose into fructooligosaccharides (FOS), prebiotic fibers that resist digestion in the small intestine and are fermented in the colon. Conventional sugar reduction replaces sugar with sweeteners and bulking agents; here, the sugar stays in the product until it is eaten.

How it works

Zya was founded in 2018 by Oxford University biochemists Joshua Sauer (CEO) and Niels Leckie (chief scientific officer), and Astanor backed it as early as 2022. It is first targeting low-moisture products such as chocolate, cereal bars, biscuits and confectionery, where the enzyme stays inactive until it reaches the stomach and dissolves in the watery environment. In moist products like yogurt or drinks, conversion would begin too early.

Validation and regulation

So far Convero's function has been shown in in-vitro gut models and preliminary pig studies. The company has also completed a toxicology program, including a 28-day rat feeding study, with results published in Toxicology Reports. In the US, Zya expects to complete a self-affirmed GRAS (Generally Recognized as Safe) determination by the end of 2026, followed by a formal submission to the Food and Drug Administration (FDA).

Production uses an established yeast platform, and the enzyme is supplied as a dry powder. It has been run at a European food-grade facility and scaled to ten times the pilot volume.

On labeling, the sugar content on the pack would remain unchanged, but accompanying text would state the composition after eating. The next hurdle is showing that results seen in laboratory models and early animal studies are reproducible in humans.

Comments

0/1500

Comments are automatically moderated. No hate, threats, personal data or spam.

Loading comments…

More in this category